BACKGROUND: Adenosine A2A receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia. METHODS: We examined the association between self-reported intake of the A2A receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson's severity, site, and initial treatment with pramipexole or levodopa. RESULTS: For subjects who consumed >12 ounces of coffee/day, the adjusted hazard ratio for the development of dyskinesia was 0.61 (95% CI, 0.37-1.01) compared with subjects who consumed <4 ounces/day. For subjects who consumed between 4 and 12 ounces/day, the adjusted hazard ratio was 0.73 (95% CI, 0.46-1.15; test for trend, P = .05). CONCLUSIONS: These results support the possibility that caffeine may reduce the likelihood of developing dyskinesia.
RCT Entities:
BACKGROUND:Adenosine A2A receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia. METHODS: We examined the association between self-reported intake of the A2A receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson's severity, site, and initial treatment with pramipexole or levodopa. RESULTS: For subjects who consumed >12 ounces of coffee/day, the adjusted hazard ratio for the development of dyskinesia was 0.61 (95% CI, 0.37-1.01) compared with subjects who consumed <4 ounces/day. For subjects who consumed between 4 and 12 ounces/day, the adjusted hazard ratio was 0.73 (95% CI, 0.46-1.15; test for trend, P = .05). CONCLUSIONS: These results support the possibility that caffeine may reduce the likelihood of developing dyskinesia.
Authors: David K Simon; Christopher J Swearingen; Robert A Hauser; Joel M Trugman; Michael J Aminoff; Carlos Singer; Daniel Truong; Barbara C Tilley Journal: Clin Neuropharmacol Date: 2008 Jul-Aug Impact factor: 1.592
Authors: Radu Constantinescu; Megan Romer; Michael P McDermott; Cornelia Kamp; Karl Kieburtz Journal: Mov Disord Date: 2007-07-15 Impact factor: 10.338
Authors: Peter A LeWitt; M Guttman; James W Tetrud; Paul J Tuite; Akihisa Mori; Philip Chaikin; Neil M Sussman Journal: Ann Neurol Date: 2008-03 Impact factor: 10.422
Authors: Frédéric Calon; Mehdi Dridi; Oleh Hornykiewicz; Paul J Bédard; Ali H Rajput; Thérèse Di Paolo Journal: Brain Date: 2004-03-19 Impact factor: 13.501
Authors: Ronald B Postuma; Julius Anang; Amelie Pelletier; Lawrence Joseph; Mariana Moscovich; David Grimes; Sarah Furtado; Renato P Munhoz; Silke Appel-Cresswell; Adriana Moro; Andrew Borys; Douglas Hobson; Anthony E Lang Journal: Neurology Date: 2017-09-27 Impact factor: 9.910